key: cord-0283496-xuj3dtu2 authors: Jesus Faustino Ramos, R.; Zhu, C.; Joseph, D. F.; Thaker, S.; LaComb, J. F.; Markarian, K.; Littmann, E. R.; Lee, H. J.; Petrov, J. C.; Monzur, F.; Morganstern, B. M.; Bucobo, J. C.; Buscaglia, J. M.; Chawla, A.; Small-Harary, L.; Gathungu, G.; Morganstern, J. A.; Yang, J.; Li, J.; Robertson, C. E.; Pamer, E. G.; Frank, D. N.; Cross, J. R.; Li, E. title: Integrated metagenomic and bile acid metabolomic analysis of human fecal microbiota transplantation for recurrent Clostridioides difficile and/or inflammatory bowel diseases. date: 2022-02-15 journal: nan DOI: 10.1101/2022.02.11.22268733 sha: 0b3dd94a7eb8b81cccfb9e71e1862fe07b2822ad doc_id: 283496 cord_uid: xuj3dtu2 Background Fecal microbiota transplantation (FMT) is an effective treatment of recurrent Clostridioides difficile (rCDI). In comparison FMT has more limited efficacy in treating either ulcerative colitis (UC) or Crohn's disease (CD), two forms of inflammatory bowel disesases (IBD). We hypothesize that FMT recipients with rCDI and/or IBD have baseline bile acid (BA)compositions that differ significantly from that of their healthy donorsand may be normalized by FMT. Aim To study the effect of single colonoscopic FMT on the microbial composition and function of recipients with rCDI and/or IBD. Methods Multi-omic analysis was performed on stools from 55 pairs of subjects and donors enrolled in two prospective single arm FMT clinical trials [ClinicalTrials.gov ID:NCT03268213, 479696, IND 15642, ClinicalTrials.gov ID: NCT03267238, IND 16795]. Fitted linear models were used to examine the effects of four recipient groups (rCDI withoutIBD, rCDI with IBD, UC without rCDI, CD without rCDI), FMT status (Donor, preFMT, 1 week postFMT, 3 months postFMT) and first order Group*FMT interactions. Results FMT was effective in preventing rCDI for up to one year in 92% of the rCDI without IBD group and 75% of the rCDI with IBD recipients. The donor/recipient Sorensen similarity index was < 0.6 in all donor/CDI recipient pairs but > 0.6 in some donor/IBD only recipient pairs at baseline. Increasing post-FMT similarity indices > 0.6 in IBD recipients, was not clearly associated with reduced fecal calprotectin levels. Fecal secondary BA levels were lower in rCDI without IBD, CDI with IBD and CD without rCDI recipients compared to donors. FMT restored secondary BA levels in these recipients. Metagenomic baiE gene and some of the 8 bile salt hydrolase (BSH) phylotype abundances were significantly correlated with fecal BA levels. Conclusion Restoration of multiple secondary BA levels, including those recently implicated in immunomodulation, are associated with restoration of fecal baiE gene counts, suggesting that 7dihydroxylation step is rate limiting. FMT of healthy donor stool is a highly effective treatment of rCDI [1] [2] [3] [4] . Patients with IBD, 70 particularly UC, indeterminate colitis (IC) and Crohn's colitis (CC), are at increased risk of 71 developing CDI [5] [6] [7] [8] [9] , and FMT is an effective treatment of rCDI in these patients [10] [11] [12] [13] [14] [15] . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted https://doi.org/10.1101/2022.02.11.22268733 doi: medRxiv preprint 5 activity [30 -32] . Modified BA pool composition has been observed in IBD patients [33] [34] [35] , with 86 altered levels of some BA epimers that exhibit potential immunomodulatory effects. colonoscopic FMT performed on a subset of 19 recipients was previously reported [36] , which 97 included: 1) 11 rCDI -IBD; 2) 3 rCDI + UC; and 3) 5 UC -rCDI. The previous results indicated 98 marked changes in β diversity (i.e. overall microbiome composition differences between groups) 99 in the rCDI + UC and rCDI -IBD groups (compared to donors). The rCDI -IBD and rCDI + UC 100 recipients had a marked decreased abundances of anaerobic taxa in the Ruminococcaceae, (e.g. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted https://doi.org/10.1101/2022.02.11.22268733 doi: medRxiv preprint 6 We now report the results of multi-omic analysis (16S rRNA gene sequencing, 111 metabolomics analysis and shotgun DNA metagenomics sequencing) of the effect of 112 colonoscopic single donor FMT in an expanded set of recipients separated into four categories: 113 1.) rCDI -IBD; 2.) rCDI + IBD; 3.) UC -rCDI; 4.) CD -rCDI (see Fig 1) (with or without IBD), the inclusion criteria were ≥ 2 recurrences despite treatment with antibiotics, 128 documented by ≥ 3 positive stool tests for CDI (see Fig 1) . For the patients with UC without a 129 history of rCDI ≥ 2x, the inclusion criterion was medication refractory UC, requiring step up therapy 130 beyond mesalamine alone. Only one of the patients in this group had a distant prior history of CDI 7 pregnancy, c) Grade 4 anemia (Hemoglobin < 6 g/dL), d) Grade 1 neutropenia (Absolute 136 Neutrophil Count <1500), e) known diagnosis of graft vs. host disease, f) major abdominal surgery 137 within the past 3 months, g) administration of any investigational drug within the past 2 months., 142 [36] . The IBD subphenotypes were classified using the Montreal classification in terms of disease (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Milli-Q water to 50% methanol content. Samples were then filtered using 96-well Acroprep Advance plates (Pall Corporation, Port Washington, NY) and analyzed by LC-MS analysis BA 184 were separated using two chromatographic methods: 1.) Agilent 1290 Infinity LC system coupled 185 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table) , except for sulfated-BAs and 3-oxo-LCA, (e.g., removal of adapters, human sequences, low-quality sequences) was conducted using 210 KneadData version 5.1 (http://huttenhower.sph.harvard.edu/kneaddata) as previously described 211 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table) , respectively at two threshold levels: 1.) 80% identity over 80% sequence and 2.) 50% 216 identity over 80% sequence. Reads corresponding to antibiotic resistance genes were identified CD -rCDI), GLMMs or GEEs were used by taking the actual counts of each OTU as the outcomes 234 that were assumed to follow a negative binomial distribution [36] . The log-transformed overall 235 sequence count for each individual at each time point was considered as an offset. Two-way 236 interaction terms (Group*FMT) were used to estimate the difference between the time points 237 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.11.22268733 doi: medRxiv preprint The characteristics of the 55 recipient/donor pairs, segregated according to donors and the four 263 groups of recipients, are summarized in Table 1 . The median age in the rCDI -IBD group was 264 significantly higher than the donor and the other three recipient groups. Significant differences in 265 the proportion of males between groups was also observed, being particularly high in the UC - Age (y) ± IQR 43 ± 25 66 ± 21 37 ± 29 37 ± 18 18 ± 4 Males 23 (42%) 8 (30%) 3 (38%) 6 (54%) 8 (89%) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abnormal 0 (0%) 6 (22%) 5 (62%) 7 (64%) 5 (56%) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Clinical outcomes for the four recipient groups. The primary endpoint for rCDI was defined as no further rCDI at 12 months after FMT in 283 rCDI recipients with or without IBD. FMT was 92% effective in preventing rCDI in the rCDI -IBD The primary endpoint for gut inflammation as measured by fecal calprotectin levels was All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Linear mixed models comparing the ShannonH α-diversity index between donor and 304 recipient pairs in each of the four groups (Fig 3) revealed significant differences between the 305 donor group and both the rCDI -IBD (P = 0.0001) and rCDI + IBD (p <0.0001) groups at baseline 306 (Pre-FMT), with resolution of these differences at the 1 week and three month time points. In 307 contrast, differences in α-diversity between donor and recipient did not reach significance for 308 either the UC -rCDI or CD -rCDI groups. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. and healthy donors as previously described [36] . Pairwise comparisons of the estimated 336 recipient/donor ratios were then carried out. 72 OTUs demonstrating significant estimated pre- FMT recipient/donor ratios with 95%CI in at least one of the four recipient groups with a FDR (q) <0.05 are listed in S7 -S14 Tables and selected taxa are highlighted in Table 3 . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Quantitative targeted analysis of BA metabolites. We initially observed relative peak differences in BA on a subset of samples, which 364 suggested that secondary BA metabolites were reduced not only in a subset of the rCDI -IBD 365 and rCDI + IBD groups [36] , but also in the CD -rCDI group (data not shown) . To further pursue 366 these findings, 23 bile acid metabolites including secondary BA epimers (see Fig 4) , which have Table) . Prior to FMT, 19 BA 369 metabolites differed significantly from the donor group by a post-hoc Dunns test with Benjamini-370 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.11.22268733 doi: medRxiv preprint and deoxycholic acid (DCA), were the predominant metabolites in the healthy donors, but low 372 levels of secondary bile acid epimers , 3-oxo-lithocholic acid (3-oxo-LCA), iso-lithocholic acid (iso-373 LCA) and isoallo-lithocholic acid (isoallo-LCA) were also detected (see Fig 4 and 5) . In contrast, (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 403 4). Fitted linear mixed models with pair wise comparisons were conducted for the remaining 3 404 BA metabolites that did not require log transformation to measure the estimated donor-pre-FMT 405 recipient differences and response post-FMT (see Table 5 ). These results indicate that FMT has 406 a significant effect on restoring secondary BA metabolite levels in rCDI -IBD, rCDI + IBD and CD 407 -rCDI recipients. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15, 2022. Conversion of unconjugated primary BA to secondary BA (e.g. CA to DCA, and CDCA to 433 LCA), is mediated by enzymes encoded by 8 genes in the BA-inducible (bai) operon (see Fig 4) , S17 Table) . Lowering the threshold for identity from 80% to 50% markedly 445 increased the baiCD gene cpm, but had only a modest effect on the baiE gene cpm. This suggested that a much larger number of bacterial genes, which may include genes not involved 447 in the BA metabolism pathways, share protein sequence homology with the baiCD protein than 448 the baiE encoded 7α-dehydroxylase. Previous studies have reported a correlation between baiCD gene counts measured using 450 degenerate PCR primers and rCDI [28, 43] . Using these degenerate primers, we observed 451 multiple amplicons with a large range of sizes after analyzing the PCR reactions by gel 452 electrophoresis, but only observed single amplicon bands using specific C. scindens and C. 453 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.11.22268733 doi: medRxiv preprint 24 hiranonis primers. Consistent with previous studies, a higher proportion of rCDI ± IBD recipients 454 lacked detectable baiE cpm compared to donors (see Fig 6) . Table) . The abundance of each BSH phlyotype was calculated as the 465 sum of the individual BSH protein sequence cpms at 80% identity. As shown in Fig 7, The 3-α-and 3-β-hydroxysteroid dehydrogenases (HSDHs) from R. gnavus and E. lenta, 475 metabolize LCA to 3-oxo-LCA and then to iso-LCA (see Fig 4) , which exhibit in vitro activity on T-476 cell regulation [30] [31] [32] . Not surprisingly, the correlations were significant between the gene counts 477 of HSDHs (80% identity) from the same taxa, however the correlation between the 3β-HSDH 478 between R. gnavus and E. lenta was not significant (see S18 Table) . No significant differences in 479 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.11.22268733 doi: medRxiv preprint the median R. gnavus 3α-HSDH cpm or 3β-HSDH cpm were observed between the donors and 480 the pre-FMT levels of the four recipient groups, although decreased estimated pre-FMT 481 recipient/donor ratios for Ruminococcus genus rRNA gene was observed in the rCDI -IBD and 482 rCDI + IBD groups (see Table 3 ). A significant difference was observed for median E. lenta β- HSDH cpms between the donors and the Pre-FMT levels of the four recipient groups (P = 0.0117), 484 with significant difference between the rCDI -IBD and the UC -rCDI groups (P = 0.0184), and 485 between the rCDI + IBD and UC -rCDI groups (P = 0.0200). Similarly, a significant difference 486 was also observed for median E. lenta α-HSDH cpms between the donors and the pre-FMT levels 487 of the four recipient groups (P = 0.0065), with significant difference between the rCDI -IBD and 488 the UC -rCDI groups (P = 0.0252), and between the rCDI + IBD and UC -rCDI groups (P = 489 0.0157). Because B. dorei has been reported to convert iso-LCA to isoallo-LCA, a DIAMOND 491 search was conducted for the putative B. dorei 5β-reductase, 5α-reductase and 3β-HSDH 492 enzymes identified by BLAST searches reported by Li et al. [32] . All three of these protein 493 sequences are significantly correlated with each other (see S19 Table) . The median cpms for 494 each of these candidate genes were significantly decreased in the rCDI + IBD group compared 495 to donors (P = 0.0003, 0.0003, <.0001 for 3β-HSDH, 5β-reductase and 5α-reductase respectively) 496 and the UC -rCDI groups (P = 0.0076, 0.0059, 0.0056 for 3β-HSDH, 5β-reductase and 5α-497 reductase respectively) and decreased in the rCDI -IBD groups compared to donors (P = 0.0002, 498 0.0007, <0.0001 for 3β-HSDH, 5β-reductase and 5α-reductase respectively) and the UC -rCDI 499 groups (P = 0.0144, 0.0202, 0.0167 for 3β-HSDH, 5β-reductase and 5α-reductase 500 respectively). This is consistent with the marked decrease in the estimated pre-FMT recipient 501 donor ratios for the Bacteroides genus rRNA gene in the rCDI -IBD and rCDI + IBD groups (see 502 Table 3 ). In order to integrate the shotgun metagenomics data with the BA metabolite data, we 504 measured the correlation between the abundances of the BA metabolizing genes (cpms) and 505 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.11.22268733 doi: medRxiv preprint fecal BA levels using linear mixed models, which clustered values from each FMT group, to 506 calculate the estimated coefficient and 95% confidence interval (CI) (see Tables 6 and 7) . Log 507 transformation was applied if the normality assumption was not satisfied. As shown in Table 6 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We report the results of integrating 16S RNA gene sequencing, shotgun metagenomics 544 sequencing and quantitative BA metabolomic analysis in human stools collected during two 545 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Decreases in secondary BA have been observed in rCDI and more recently in IBD 550 [28, 49] . In this study, we observed a general reduction in the levels of secondary BA including 551 the immunomodulatory derivatives of LCA in the rCDI -IBD, the rCDI + IBD and CD -rCDI groups Based on gel electrophoresis analysis of products of the baiCD gene PCR assay, we suspect 568 there may be significant homology between that gene sequence and other genes which are 569 unrelated to the BA transformation pathway. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. reductase, 5α-reductase and 3β-HSDH genes to the production of secondary BA epimers may 591 be reduced simply because more upstream processes drastically reduce levels of secondary BA 592 substrates, such as LCA and DCA. A major limitation of this study is the small number of subjects in each of the three IBD 594 recipient groups and that these studies were single arm in design. Unfortunately, the COVID 595 pandemic has essentially forced a halt to these clinical trials. Nevertheless, the samples and 596 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.11.22268733 doi: medRxiv preprint multi-omic datasets generated from these samples will continue to provide an important resource 597 for characterizing the effect of FMT on microbial function as further progress is made in identifying 598 bacterial strains and enzymes involved in the biotransformation of BAs and other metabolites. Treatment of refractory/recurrent C. difficile-associated disease by 619 donated stool transplanted via colonoscopy: a case series of 12 patients No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Fecal 625 transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile 626 infection European 628 consensus conference on faecal microbiota transplantation in clinical practice Incidence of Clostridium difficile 631 infection in inflammatory bowel disease Impact of Clostridium difficile on inflammatory bowel disease Impact of Clostridium 635 difficile infection on pediatric inflammatory bowel disease Clostridium difficile 637 and pediatric inflammatory bowel disease: a prospective, comparative, multicenter, ESPGHAN 638 study The incidence and 640 outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel 641 disease Microbiome 643 changes associated with sustained eradication of Clostridium difficile after single faecal 644 microbiota transplantation in children with and without inflammatory bowel disease No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15 Fecal microbiota transplantation is 648 safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with 649 inflammatory bowel disease Inflammatory 651 bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium 652 difficile infection Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile 655 infection affected by underlying inflammatory bowel disease Long-term safety and efficacy of fecal microbiota 657 transplantation in the treatment of Clostridium difficile infection in patients with and without 658 inflammatory bowel disease: a tertiary care center's experience Fecal microbiota 661 transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel 662 disease: a single-center experience Alteration 664 of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients 665 with chronic active ulcerative colitis The taxonomic 667 composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal 668 microbiota transplantation in therapy refractory ulcerative colitis No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Fecal microbiota 674 transplantation induces remission in patients with active ulcerative colitis in a randomized 675 controlled trial Single fecal microbiota 677 transplantation failed to change intestinal microbiota and had limited effectiveness against 678 ulcerative colitis in Japanese patients Efficacy and safety of 680 single fecal microbiota transplantation for Japanese patients with mild to moderately active 681 ulcerative colitis Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised 684 placebo-controlled trial Effect of fecal 686 microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized 687 clinical trial Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota 690 transplantation Donor species 692 richness determines faecal microbiota transplantation success in inflammatory bowel disease No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15 Fecal microbiota 698 transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study Precision microbiome 701 reconstitution restores bile acid mediated resistance to Clostridium difficile Consequences of bile salt 704 biotransformations by intestinal bacteria Bile acid metabolites control TH17 and 706 Treg cell differentiation Bacterial 708 metabolism of bile acids promotes generation of peripheral regulatory T cells A bacterial bile acid metabolite 711 modulates Treg activity through the nuclear hormone receptor NR4A1 Gut 714 microbiome structure and metabolic activity in inflammatory bowel disease Human gut bacteria 717 produce TH17-modulating bile acid metabolites No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15 Longitudinal microbiome 722 analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium 723 difficile infection and/or ulcerative colitis The Montreal classification of 725 inflammatory bowel disease: controversies, consensus, and implications Endoscopic 727 scoring indices for evaluation of disease activity in ulcerative colitis Responsiveness of 730 endoscopic indices of disease activity for Crohn's disease Fast and sensitive protein alignment using DIAMOND Explicet: 735 graphical user interface software for metadata-driven management, analysis and visualization of 736 microbiome data Drug-738 resistant E. coli bacteremia transmitted by fecal microbiota transplant Antimicrobial resistance gene 741 acquisition and depletion following fecal microbiota transplantation for recurrent Clostridium 742 difficile infection No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted BaiCD gene 744 cluster abundance is negatively correlated with Clostridium difficile infection Clostridium scindens is present in the gut 747 microbiota during Clostridium difficile infection: a metagenomic and culturomic analysis Taxonomic profiling and populational 750 patterns of bacterial bile salt hydrolase (BSH) genes based on worldwide human gut microbiome Bile salt hydrolases: structure and function, substrate preference, and 753 inhibitor development Bile salt hydrolases: gatekeepers of bile 755 acid metabolism and host-microbiome crosstalk in the gastrointestinal tract Connecting 758 dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases Metagenomic analysis of bile salt biotransformation 761 in the human gut microbiome Novel bile acid 763 biosynthetic pathways are enriched in the microbiome of centenarians No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 15 Institutional review board approved protocol for Clinical Trials Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) Chromatographic and quantitation strategy for the BA and internal standards 774 (ISTD) measured Bile acid metabolizing enzyme genes used in DIAMOND custom search Individual characteristics of the rCDI -IBD recipients Individual characteristics of the rCDI + IBD recipients Individual characteristics of the UC -rCDI recipients Individual characteristics of the CD -rCDI recipients Significant (FDR < 0.05) estimated pre-FMT recipient/donor ratios (95% CI) of the Significant (FDR < 0.05) estimated pre-FMT recipient/donor ratios (95% CI) of the Significant (FDR < 0.05) estimated pre-FMT recipient/donor ratios (95% CI) of We want to thank the recipients and donors for participating in this study. We acknowledge All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.11.22268733 doi: medRxiv preprint